Abstract. Programmed death ligand-1 (PD-L1) is a potentially important tumor immunotherapy target. However, whether PD-L1 expression is associated with survival in nasopharyngeal carcinoma (NPC) remains controversial. The aim of the present study was to investigate the association between PD-L1 expression and prognosis in NPC. The expression of PD-L1 was assessed in tumor specimens from 120 patients with NPC using immunohistochemistry. Staining was evaluated using the H-score method. The associations between PD-L1 expression and clinical characteristics and prognosis were analyzed. Overall, 78% of the patients had stage I-III and 22% had stage IV disease. The estimated 5-year overall survival (OS) and disease-free survival (DFS) rates for the entire cohort were 87.5 and 70.1%, respectively. PD-L1 expression was detected in 85 (71%) patients and was localized to the tumor cells. High tumor expression of PD-L1 (median H-score ≥5) was associated with significantly poorer OS (P=0.023) and DFS (P=0.002). Univariate analysis indicated that low PD-L1 expression was associated with better DFS compared with high PD-L1 expression (HR=0.163, 95% CI: 0.044-0.600, P=0.006 for DFS). Multivariate analysis revealed that T stage (HR=8.190, P=0.023) and PD-L1 expression level (HR=0.124, 95% CI: 0.031-0.509; P=0.001) served as independent prognostic factors for DFS. In conclusion, tumor PD-L1 expression was found to be a significant prognostic factor in NPC, and high PD-L1 expression may be of prognostic value for recurrence and metastasis following conventional treatments.
Introduction
Nasopharyngeal carcinoma (NPC) is disproportionately common in southern China (1) , where the annual incidence is 15-50/100,000 individuals (2) . Radiotherapy (RT) is the primary treatment for NPC. While advances in tumor imaging and RT technologies have increased 5-year disease-free survival (DFS) to 77% for early-stage disease (3), distant metastasis remains a major obstacle to further improvements in survival (4) .
The immune checkpoints proteins programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been reported to be important immunotherapy targets. The antitumor efficacy of blocking these targets has been confirmed in vitro as well as in vivo. Blocking the PD-1/PD-L1 signaling pathway represents a promising immunotherapeutic strategy to enhance the ability of the immune system to target cancer cells (5, 6) .
PD-L1 is expressed in a variety of tumor types, including esophageal, gastrointestinal tract, pancreatic, breast, lung and kidney carcinomas (7, 8) . Several studies have indicated that tumor PD-L1 expression is associated with poor prognosis (9, 10) ; however, it remains unclear whether such an association exists in NPC. The aim of the present study was to investigate the associations between tumor PD-L1 expression and prognosis in NPC.
Patients and methods
Patients and sample collection. Two cohorts of patients with NPC were enrolled: 62 patients with primary biopsy-confirmed NPC diagnosed between January 2009 and January 2012 at the Second Affiliated Hospital of Nanchang University (Nanchang, China) and 58 patients with primary biopsy-confirmed NPC diagnosed between January 2010 and May 2015 at the People's Hospital of Fuzhou (Fuzhou, China). Formalin-fixed paraffin-embedded tissues were obtained from the initial diagnostic biopsy specimens. Information on the clinical course of each patient, including sex, age, tumor staging and smoking history, was obtained from medical records. Complete follow-up data were available for all 62 patients treated at the Second Affiliated Hospital of Nanchang University. Data on disease and vital status for these patients were obtained using The staining was independently assessed by two surgical pathologists using a semi-quantitative scale that ranges from 0 to 100% for the proportion of PD-L1-positive cancer cells. The mean score for replicate samples was recorded. Two groups of patients were created based on receiver operating characteristic (ROC) curves. According to the results, 20% was set as the cut-off value for dividing the samples into high PD-L1 and low PD-L1 group for DFS. The areas under the ROC curves were 0.827.
Statistical analysis.
The associations between PD-L1 expression and clinicopathological characteristics were assessed using Pearson's χ 2 test. Overall survival (OS) and DFS were compared using the Kaplan-Meier method and log-rank tests. Cox proportional hazards analysis was performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the associations between tumor PD-L1 expression and survival outcome. Multivariate survival analysis was conducted for all of the parameters using the Cox regression model. All analyses were performed using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Two-sided P-values <0.05 were considered to indicate statistically significant differences.
Results
Clinicopathological characteristics. The 120 patients in this cohort ranged in age from 17 to 69 years (median, 48 years). A total of 78% (79/102) of the patients had stage I-III and 22% (23/102) had stage IV NPC according to the 1997 American Joint Committee on Cancer staging system (11) . All the cases were classified as undifferentiated non-keratinizing NPC. The estimated 5-year OS and DFS rates for the group eligible for survival analysis (the 62 patients treated at the Second Affiliated Hospital of Nanchang University) were 87.5 and 70.1%, respectively. Other clinicopathological characteristics are summarized in Table I .
PD-L1 protein is frequently expressed in NPC.
To investigate whether PD-L1 is expressed in NPC similar to its expression in other tumors, PD-L1 protein expression was assessed using immunohistochemistry in tumor samples from 120 patients with NPC. The PD-L1 protein was found to be frequently expressed in NPC. PD-L1 expression was detected in 71% (85/120) of the tumor samples. The PD-L1 protein was localized to the cell membrane of the primary tumor cells (Fig. 1A) and metastatic lymph nodes (Fig. 1D) . Moreover, PD-L1 protein expression was significantly higher in the tumor cells compared with that in adjacent non-cancerous tissues (Fig. 1B and C) .
Associations between PD-L1 expression and the clinicopathological characteristics of NPC. To identify the clinical relevance of PD-L1 expression in NPC, the associations between PD-L1 expression and clinicopathological characteristics of NPC, such as sex, age, smoking history, histology and TNM stage, were examined. The 120 patients were further classified into the high PD-L1 (n=54) and low PD-L1 (n=66) groups based on the tumor PD-L1 expression level. The results revealed that high PD-L1 expression was significantly associated with age (P= 0.006) and stage (P=0.036), but not the other clinical characteristics examined (Table I) . Table I . Associations between PD-L1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma. 
Associations between PD-L1 expression and prognosis in NPC.
Estimated 5-year OS and DFS for the group eligible for survival analysis (the 62 patients treated at Second Affiliated Hospital of Nanchang University) were 87.5 and 70.1%, respectively ( Fig. 2A and B) . The OS and DFS curves for the high PD-L1 and low PD-L1 groups are shown in Fig. 2C and D. As expected, patients with high PD-L1 expression had significantly poorer OS (P= 0.023) and DFS (P=0.002) compared with patients with low PD-L1 expression. Univariate Cox proportional regression analysis revealed that T stage (HR=4.081, 95% CI: 1.130-18.14; P=0.048) and PD-L1 expression (HR=0.163, 95% CI: 0.044-0.600; P=0.006) were prognostic factors for DFS (Table II) . A multivariate analysis using the Cox regression model revealed that T stage (HR=8.190, 95% CI: 1.355-18.152; P=0.023) and PD-L1 expression level (HR=0.124, 95% CI: 0.031-0.509; P=0.001) served as independent prognostic factors for DFS.
Discussion
Tumor immune evasion is considered to be a hallmark of cancer (12) . Blockade of immune checkpoints represents a promising therapeutic approach to activate antitumor immunity (13) . PD-L1 is recognized as an important immunosuppressive factor (14) and is upregulated in a variety of Epstein-Barr virus (EBV)-associated malignancies (15) , although its expression in NPC, an EBV-associated malignancy with a higher metastatic potential compared with other head and neck cancers, is poorly characterized (16, 17) . The expression of PD-L1 is associated with the treatment response to nivolumab, an anti-PD-1 antibody, in a subset of tumor types (18) . The efficacy of immune-targeted therapies in EBV-associated malignancies requires further investigation. Therefore, assessing the expression of biomarkers such as PD-L1 may help identify patients who will benefit from immunomodulatory agents. However, variation in PD-L1 expression rates previously observed in a study of various cancers has been attributed to differences in cut-off values, antibodies, and study populations (19, 20) . In lung cancer characterized by PD-L1 expression, the expression rates varied from 24 to 60% using the same 5% cut-off value (21, 22) , and from 21 to 95 % according to different cut-off values of 1, 10 and 50% (23, 24) . Thus, the use of PD-L1 expression as a marker remains controversial due to the different antibodies used, the method of assessment and the different thresholds.
In the present study, tumor PD-L1 expression and its association with the clinicopathological characteristics and survival outcomes of NPC were analyzed. The PD-L1 protein was found to be frequently expressed in NPC and high tumor expression of PD-L1 was prognostic for poor DFS. Fang et al (25) reported that 89% (16/18) of EBV-associated NPC cases expressed PD-L1 in the malignant tumor cells, which is consistent with the findings of our study. Additionally, high expression of PD-L1 was also found to be associated with poor clinical prognosis in renal cell carcinoma, hepatocellular cancer and breast cancer (26) (27) (28) (29) .
Previous studies demonstrated that constitutively-activated oncogenic pathways may upregulate PD-L1. Parsa et al reported loss of phosphatase and tensin homolog and resulting activation of the phosphoinositide 3-kinase pathway significantly upregulates PD-L1 in glioma (30) . Marzec et al found constitutive activation of nucleophosmin/anaplastic lymphoma kinase induces PD-L1 expression via signal transducer and activator of transcription 3 (31) . The mechanism through which PD-L1 is upregulated in NPC has not been fully elucidated. Fang et al observed that high levels of PD-L1 expression in EBV-infected NPC cells were associated with latent membrane protein 1 (LMP1)-mediated oncogenic pathways and immune modulation via excretion of interferon-γ (25) . These results indicated that inhibition of the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may provide a clinical benefit during the treatment of EBV-associated NPC. In conclusion, PD-L1 is frequently upregulated in NPC, and high PD-L1 expression was associated with poor prognosis. These findings implicate PD-L1 in the development of NPC and highlight the potential of PD-L1 as a therapeutic target for NPC. Patients with NPC whose tumors express high levels of PD-L1 may be optimal candidates for clinical trials of strategies aiming to block PD-L1.
